HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: 01.wnl.0000192260.33106.bbv1 66/1_suppl_1/S20    most recent Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Engel, W. K. Articles by Askanas, V. Search for Related Content PubMed PubMed Citation Articles by Engel, W. K. Articles by Askanas, V.

Inclusion-body myositis

Clinical, diagnostic, and pathologic aspects

From the Neuromuscular Center, Department of Neurology, University of Southern California Keck School of Medicine, Good Samaritan Hospital, Los Angeles, CA.

Address correspondence and reprint requests to Dr. W. King Engel, USC Neuromuscular Center, Good Samaritan Hospital, 637 S. Lucas Ave, Los Angeles, CA 90017-1912; email: askanas{at}hsc.usc.edu

The diagnostic aspects of sporadic inclusion-body myositis (s-IBM), and a few comments on our own approach to its treatment, are presented to foster the goals of this symposium, which was organized to provoke new ideas concerning the cause and treatment of this currently unsolvable disease. s-IBM is the most common, progressive, debilitating muscle disease beginning in persons over age 50 years, and it is more common in men. Diagnostic parameters reviewed are clinical, muscle-biopsy histochemistry, electrophysiologic and CSF evaluations. Overall, the degenerative phenomena in s-IBM muscle fibers seem to be the major cause of the progressive, unstoppable weakness, rather than the lymphocytic inflammation. Available treatments are of only slight, temporary benefit for only some s-IBM patients, indicating a desperate need for definitive therapies.

This article was previously published in electronic format as an Expedited E-Pub at www.neurology.org.

Supported by grants from the National Institutes of Health (NS31836, NS34103 and AG16768 Merit Award), the Muscular Dystrophy Association, The Myositis Association (V.A.), and the Helen Lewis Research Fund.

Disclosure: The authors report no conflicts of interest.

Received June 22, 2005. Accepted in final form October 14, 2005.

This article has been cited by other articles:

				C. E. Finch A perspective on sporadic inclusion-body myositis: The role of aging and inflammatory processes Neurology, January 24, 2006; 66(1_suppl_1): S1 - S6. [Abstract] [Full Text] [PDF]

				V. Askanas and W. K. Engel Inclusion-body myositis: A myodegenerative conformational disorder associated with A{beta}, protein misfolding, and proteasome inhibition Neurology, January 24, 2006; 66(1_suppl_1): S39 - S48. [Abstract] [Full Text] [PDF]